Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca gains rights to Almirall’s respiratory franchise
As part of the deal, AstraZeneca agreed to pay Almirall about $875m of initial consideration, and up to $1.22bn in development, launch and sales-related milestones. The acquisition gives
As part of the deal, AstraZeneca agreed to pay Almirall about $875m of initial consideration, and up to $1.22bn in development, launch and sales-related milestones. The acquisition gives
Dihon’s OTC product portfolio includes Kang Wang indicated to treat dandruff and other scalp disorders, and Pi Kang Wang, an antifungal cream, as well as TCM product Dan
At the time of data cutoff, a total of 41 patients were enrolled with tumor types including NSCLC, head and neck, small cell lung, colorectal and breast cancers,.
Elocta is the trade name of rFVIIIFc in Europe and is also called as Eloctate in the US, Canada, and Australia, where it is approved to treat hemophilia
The FDA committee voted nine to one to recommend approval of once-daily Savaysa 60mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE)
Ofatumumab is a monoclonal antibody designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes. The transfer of
NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. The open-label trial will evaluate the safety and clinical effects of NTCELL in patients
Construction has already started and the new Diabetes Research House facility is scheduled to be opened in early 2016. Following completion, the new Diabetes Research House will be
The trial is designed to assess the efficacy and safety of enzalutamide in patients with prostate cancer that has biochemically recurred following definitive local therapy with radical prostatectomy
XIGDUO XR is a combination of two anti-hyperglycemic agents, dapagliflozin and metformin hydrochloride (HCl) extended-release in a once-daily oral tablet. It is the first and only once-daily combination